We have previously used isobologram analysis to confirm synergistic interaction among HER2 and CDK4/6 inhibitors in breast cancers, which serves as a positive control for the identification of synergy by drug-drug ‘checkerboard’ experiments (Goel et al., 2016). The gene discussed is CDK4; the disease is breast cancer.